[Mycophenolate mofetil for induction of remission in Wegener's granulomatosis].
Kötter
I
I
Abteilung Innere Medizin II (Hämatologie, Onkologie, Immunologie, Rheumatologie, Pulmologie), Medizinische Universitätsklinik Tübingen, Otfried-Müller-Strasse 10, 72076, Tübingen, Germany. Ina.Koetter@med.uni-tuebingen.de
D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction
D007166:Immunosuppressive Agents; D011239:Prednisolone; D009173:Mycophenolic Acid
QJM. 2000 Jul;93(7):433-9
10874052
Arthritis Rheum. 2006 Sep;54(9):2970-82
16947528
Clin Rheumatol. 2007 Oct;26(10):1711-5
17502992
Arthritis Rheum. 2005 Aug;52(8):2461-9
16052573
J Am Soc Nephrol. 2003 Feb;14 (2):440-7
12538745
Rheumatology (Oxford). 2004 Mar;43(3):315-20
14963200
Scand J Rheumatol. 2005 May-Jun;34(3):229-32
16134730
J Rheumatol. 2003 Jan;30(1):80-8
12508394
Clin Rheumatol. 2005 Jun;24(3):251-7
15940558